VEGFA and age-related macular degeneration: Pegaptanib is a 28-base ssAO developed to specifically bind to and block the activity of vascular endothelial growth factor (VEGF)165, the VEGF isoform primarily responsible for abnormal vascular growth and permeability in wet age-related macular degeneration (AMD), while sparing the physiological isoform VEGF121 [33,37].